share_log

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15

Needham维持对递归制药的买入,将目标股价下调至15美元
Benzinga ·  2023/11/09 17:56

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 to $15.

Needham分析师吉尔·布鲁姆维持Recursion Pharmicals(纳斯达克股票代码:RXRX)的买入,并将目标股价从17美元下调至15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发